Please login to the form below

Not currently logged in
Email:
Password:

UCB appoints Peter Theil head of non-clinical development

He joins the Belgium pharma company from Genentech

Peter Theil has joined UCB as vice president, head of non-clinical development for UCB's New Medicines research arm.

He joins the Belgium pharma company from Genentech, where he was head of early development, pharmacokinetic/pharmacodynamics sciences.

At UCB he will be part of New Medicine's leadership team and will be based in Braine, Belgium.

UCB said Theil's scientific knowledge, organisational and leadership skills would invaluable in continuing it unique emphasis and success in developing both small and large molecules.

Peter is the second new member of the New Medicines leadership team, following the recent appointment of Duncan McHale, who joined UCB as VP head of global exploratory development.

McHale moved to the company from AstraZeneca, where he was held the role of head of projects, VP personalised medicine and biomarkers.

28th November 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics